Startseite Kongressberichte 2019 ESMO 2019 Press Briefings Gastrointestinal and genitourinary cancers

New Results from JAVELIN Renal 101:

A year ago at the ESMO 2018 press briefing the JAVELIN Renal 101 study results were reported:

Now at ESMO 2019 new data about JAVELIN renal 101 were reported:

Conclusions:  Pts with sRCC who received A + Ax had PFS and ORR benefit over S, supporting the results in the overall trial population. This analysis provides insight into the biology of an aggressive subtype of RCC and suggests a potential new treatment option.

Conclusions  A + Ax resulted in greater shrinkage of the primary renal tumour vs S in pts with aRCC who did not undergo uCN. This is the first report of the efficacy of immuno-oncology + tyrosine kinase inhibitor therapy on the primary tumour in the context of metastatic RCC and provides insight into future neoadjuvant strategies in aRCC.